Show simple item record

FieldValueLanguage
dc.contributor.authorAhmad, Amina
dc.date.accessioned2020-10-02
dc.date.available2020-10-02
dc.date.issued2020en_AU
dc.identifier.urihttps://hdl.handle.net/2123/23518
dc.description.abstractVectors based on adeno-associated virus (AAV) are emerging as systems of choice for clinical in vivo gene transfer for effective and persistent transgene expression. The promise for further success is heralded by discovery of AAV capsids with higher tissue tropisms and the rapid improvement in technology encourages development of novel approaches for disease treatment. The current project has sought to develop liver targeting strategies to modulate innate immunity through elevated serum protein levels. Vectors encoding DNaseI or complement regulatory proteins Factor I (FI) or a modified Factor H (FH) protein were packaged to permit efficient transduction of the murine liver. Studies with FI extend previous in vitro studies which found elevated FI levels normalises the complement Alternative Pathway in individuals with hyperactive “complotypes” at risk of disease. AAV delivery induced a 5-fold in vivo increase in murine serum FI levels leading to a 50% reduction in complement activity. Further studies to demonstrate bioactivity were hampered by availability of suitable models. Elevated FI did not prevent renal damage in models of ischemia reperfusion injury or FH deficiency but indicated that (i) AAV delivery of the human FH “minigene” is effective as gene replacement therapy and (ii) FI is not a limiting cause of pathology in FH-deficient mice. Elevation of serum DNaseI levels was pursued based on multiple reports indicating exogenous DNaseI is a promising approach to slow autoimmunity. AAV gene delivery induced high (>150-fold) and sustained (>6 months) activity of serum DNaseI in lupus-prone NZBWF1 mice resulting in decreased glomerular deposition of C3 and IgG. However, there were limited effects on autoantibodies, renal pathology and animal survival. Collectively, the current data demonstrate potential for continued development of AAV immunotherapy through optimised transgene delivery and further exploration in relevant models.en_AU
dc.language.isoenen_AU
dc.publisherUniversity of Sydneyen_AU
dc.subjectgene therapyen_AU
dc.subjectAAVen_AU
dc.subjectautoimmunityen_AU
dc.subjectSLEen_AU
dc.subjectcomplementen_AU
dc.titleTherapeutic Modulation of Complement Activity and DNaseI Expression using AAVmediated Gene Transferen_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen_AU
usyd.departmentThe Children’s Medical Research Instituteen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorAlexander, Ian


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.